Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults
| Autor: | Meredith Hawkins, Kehao Zhang, Jessica C. Mar, Jill P. Crandall, Nir Barzilai, Noah A Bloomgarden, Ameya S Kulkarni, Valentin Anghel, Erika F. Brutsaert, Michael Pollak |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty Aging endocrine system diseases medicine.medical_treatment Subcutaneous Fat Adipose tissue Peroxisome proliferator-activated receptor Gene Expression mTORC1 Biology Biological pathway Transcriptome 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Hypoglycemic Agents Muscle Skeletal Aged chemistry.chemical_classification Cross-Over Studies upstream regulators Insulin Skeletal muscle Short Take Cell Biology Metformin 3. Good health 030104 developmental biology Endocrinology medicine.anatomical_structure chemistry biguanides Female metabolism 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Aging Cell |
| ISSN: | 1474-9726 |
| Popis: | Summary Administration of metformin increases healthspan and lifespan in model systems, and evidence from clinical trials and observational studies suggests that metformin delays a variety of age‐related morbidities. Although metformin has been shown to modulate multiple biological pathways at the cellular level, these pleiotropic effects of metformin on the biology of human aging have not been studied. We studied ~70‐year‐old participants (n = 14) in a randomized, double‐blind, placebo‐controlled, crossover trial in which they were treated with 6 weeks each of metformin and placebo. Following each treatment period, skeletal muscle and subcutaneous adipose tissue biopsies were obtained, and a mixed‐meal challenge test was performed. As expected, metformin therapy lowered 2‐hour glucose, insulin AUC, and insulin secretion compared to placebo. Using FDR |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text